Investors Capital Advisory Services’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Investors Capital Advisory Services’s Portfolio BIB Stock Details BIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$633K	Sell	16,317 -1,257	-7%	-$54.2K	0.12%	226
2016 Q1	$718K	Buy	+17,574	New	+$777K	0.14%	198

Other funds holding BIB

RIA

RPG Investment Advisory Pleasanton, California $829M AUM 36.68% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Timber Hill Greenwich, Connecticut $15.4M AUM 30.7% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

CMT Trading Chicago, Illinois $22.4M AUM 78.15% 1-Year Est. Return

Investors Capital Advisory Services's BIB Position: Q2 2016 in Review

Investors Capital Advisory Services reduced its ProShares Ultra NASDAQ Biotechnology (BIB) stake by 7.2% in Q2 2016, selling an estimated $54.2K and leaving 16,317 shares worth $633K. The position accounts for 0.12% of the portfolio, ranked #226.

Investors Capital Advisory Services first reported a position in BIB in Q1 2016 and has held it in 2 quarters since. The position peaked at $718K in Q1 2016. 31 funds tracked by Wall St. Rank hold BIB as of Q2 2016.

Investors Capital Advisory Services held 16,317 shares of ProShares Ultra NASDAQ Biotechnology worth $633K as of Q2 2016.
Investors Capital Advisory Services sold 1,257 ProShares Ultra NASDAQ Biotechnology shares in Q2 2016, an estimated $54.2K.
ProShares Ultra NASDAQ Biotechnology made up 0.12% of Investors Capital Advisory Services's portfolio in Q2 2016, its #226 holding.
Investors Capital Advisory Services first reported a position in ProShares Ultra NASDAQ Biotechnology in Q1 2016 and has held it in 2 quarters since.
Investors Capital Advisory Services's ProShares Ultra NASDAQ Biotechnology position peaked at $718K in Q1 2016.
31 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q2 2016.

Based on Investors Capital Advisory Services's 13F filing for Q2 2016, filed 2 Aug 2016.